<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257254</url>
  </required_header>
  <id_info>
    <org_study_id>BTG-001652-01</org_study_id>
    <nct_id>NCT03257254</nct_id>
  </id_info>
  <brief_title>Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)</brief_title>
  <acronym>VIEW-VLU</acronym>
  <official_title>Observational Study of the Effect of VarIthena® on Wound Healing in the Treatment of Venous Leg Ulcers Resulting From Chronic Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12 month, multicenter, open-label registry to observe chronic venous insufficiency&#xD;
      resulting in VLU treated with Varithena.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 12 month, multicenter, open-label registry is designed to collect treatment and outcome&#xD;
      data related to participants treated with Varithena for great saphenous vein (GSV) system&#xD;
      and/or anterior accessory saphenous vein (AASV) incompetence resulting in VLU. Participant&#xD;
      are treated per Investigator's Standard of Care (SoC) and in accordance with the Full&#xD;
      Prescribing Information (FPI) and Instructions for Use (IFU). For participants with healed&#xD;
      ulcers during the 12 month follow-up period, VLU recurrence information is collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Actual">September 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 18, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Epithelial Migration Measured by Change in Perimeter of Wound</measure>
    <time_frame>Weekly up to wound closure or 12 months, whichever occurs first</time_frame>
    <description>Decrease in wound perimeter per week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Closure Rate</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Number of healed wounds at 12 weeks post treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Wound Closure</measure>
    <time_frame>Weekly up to wound closure or 12 months, whichever occurs first</time_frame>
    <description>Mean number of weeks to wound closure.</description>
  </primary_outcome>
  <enrollment type="Actual">82</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varithena</intervention_name>
    <description>Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants classified C6 on Clinical-Etiology-Anatomy-Pathophysiology (CEAP)&#xD;
        classification with active VLU resulting from venous insufficiency of the GSV system and/or&#xD;
        AASV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women; age ≥18&#xD;
&#xD;
          -  Investigator has selected Varithena® to treat participants classified C6 with chronic&#xD;
             (≥3 months) VLU resulting from GSV and/or AASV incompetence&#xD;
&#xD;
          -  Wound can be visualized in one plane to allow for image collection of the entire wound&#xD;
             in one photograph, or if wound is circumferential, participant must be able to capture&#xD;
             the entire wound using multiple photographs taken from directly above the wound&#xD;
             (straight on)&#xD;
&#xD;
          -  Reflux &gt;500 milliseconds (ms) on duplex ultrasound&#xD;
&#xD;
          -  Willing and able to collect wound photographs and data using an application installed&#xD;
             on a tablet&#xD;
&#xD;
          -  Willing and able to return for scheduled follow-up and wound care visits&#xD;
&#xD;
          -  Ability to comprehend and sign informed consent form (ICF) and complete questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to Varithena® 1% in accordance with the FPI&#xD;
&#xD;
          -  Any serious concomitant disease, per physician's discretion, that confounds wound&#xD;
             healing, including malignant changes of wound&#xD;
&#xD;
          -  Concomitant heat ablation, or heat ablation of index leg within 6 weeks prior to&#xD;
             treatment with Varithena®&#xD;
&#xD;
          -  Significant arterial disease or ankle-brachial pressure index (ABPI) ≤0.8&#xD;
&#xD;
          -  In the opinion of Investigator, wound would close within 12 weeks without additional&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael Shao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Covenant Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Experts</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Covenant Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Venous Institute of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Cincinnati -West Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Totality</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular, PLLC</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Vascular</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J7S2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSV</keyword>
  <keyword>AASV</keyword>
  <keyword>Vein</keyword>
  <keyword>Venous</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Varicose Vein</keyword>
  <keyword>VLU</keyword>
  <keyword>venous insufficiency</keyword>
  <keyword>venous disease</keyword>
  <keyword>chronic VLU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 28, 2021</submitted>
    <returned>October 25, 2021</returned>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

